Necrosis News and Research

RSS

UMass Amherst epidemiologist investigates risk of early menopause

The estimated 10 percent of women in Western nations who enter menopause before age 45 have an elevated risk of cardiovascular disease, as well as lower fertility. Now epidemiologist Elizabeth Bertone-Johnson at the University of Massachusetts Amherst is conducting the first large study to investigate whether vitamin D deficiency, inflammatory factors, hormones and other factors are associated with risk of early menopause, funded by NIH.

29 Oct 2014

FVI equation predicts blood flow for DIEP reconstruction

For women undergoing breast reconstruction using the advanced "DIEP" technique, a simple formula can reliably tell whether there will be sufficient blood flow to nourish the DIEP flap, reports a paper in Plastic and Reconstructive Surgery—Global Open®, the official open-access medical journal of the American Society of Plastic Surgeons (ASPS).

8 Oct 2014

NF-kB molecule may help malignant cells hide from the immune system

A molecule that helps cancer cells evade programmed self-destruction, an internal source of death, might also help malignant cells hide from the immune system, an external source of death.

8 Oct 2014

Animal study suggests ibuprofen can reduce lung inflammation in elderly

New research shows that the lungs become more inflammatory with age and that ibuprofen can lower that inflammation.

3 Oct 2014

GILZ protein key to preventing bone loss, researchers report

A small protein named GILZ appears to protect against the bone loss that often accompanies arthritis and its treatment, researchers report.

15 Sep 2014

Expert creates new evidence-based guideline for managing sickle cell disease

An expert panel has created a new evidence-based guideline for managing sickle cell disease (SCD), with a strong recommendation for the use of the drug hydroxyurea and transfusion therapy for many individuals with SCD, although high-quality evidence is limited, with few randomized clinical trials conducted for this disease, according to an article in the September 10 issue of JAMA.

10 Sep 2014

Restarting infliximab therapy after drug holiday is safe for patients with IBD

Restarting infliximab therapy after a drug holiday is safe and effective for patients with inflammatory bowel disease (IBD), according to a new study1 in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

8 Sep 2014

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the acquisition of a novel orphan drug candidate, known as SGX301 (synthetic hypericin).

8 Sep 2014

Study explores role of self-esteem and social adjustment in children and adolescents

In the current issue of Psychotherapy and Psychosomatics a Group of Greek investigators is reporting on a study exploring the role of self-esteem and social adjustment in children and adolescents.

4 Sep 2014

UT Southwestern faculty awarded CPRIT grants to combat cancer

UT Southwestern Medical Center faculty have received 19 grants totaling more than $26 million from the Cancer Prevention and Research Institute of Texas to expand cancer screenings, investigate the effectiveness and viability for cancer therapies and radiation treatments, conduct research into cancer biology, and recruitment.

29 Aug 2014

Many people with severe rheumatoid arthritis failing to take expensive medication

Large numbers of people with severe rheumatoid arthritis are failing to take expensive medication as prescribed, according to a new multi-centre study led by researchers in Manchester.

From The University of Manchester 28 Aug 2014

Cilag GmbH International acquires biopharmaceutical company, Covagen AG

Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired Covagen AG, a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb® technology platform.

25 Aug 2014

Research findings call for clinical testing of relevant drugs to prevent NASH

Non-alcoholic fatty liver disease (NAFLD) is a common affliction, affecting almost 30 percent of Americans, with a significant number suffering from its most severe form, called non-alcoholic steatohepatitis or NASH, which can lead to cirrhosis and liver cancer. In recent years, NASH has become the leading cause of liver transplantation.

19 Aug 2014